Compare SKIL & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKIL | RLYB |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | 2261 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 28.7M |
| IPO Year | N/A | 2021 |
| Metric | SKIL | RLYB |
|---|---|---|
| Price | $3.71 | $9.50 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 148.0K | ★ 243.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $600,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.72 | $0.22 |
| 52 Week High | $23.00 | $11.49 |
| Indicator | SKIL | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 31.34 | 71.26 |
| Support Level | $3.72 | $0.48 |
| Resistance Level | $4.84 | $11.49 |
| Average True Range (ATR) | 0.47 | 0.89 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 0.45 | 68.17 |
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.